文献速递前列腺癌

前列腺MRI表现差异:前列腺活检协作组数据

Variation in Prostate Magnetic Resonance Imaging Performance: Data from the Prostate Biopsy Collaborative Group.
PubMed 文献 · Eur Urol Oncol · 2025-05-02

该研究基于前列腺活检协作组13个中心7320例患者数据,分析2010-2023年间接受多参数MRI及靶向活检且PI-RADS≥3分者的PI-RADS评分分布及GG≥2前列腺癌检出风险。结果显示不同中心间PI-RADS 4/5赋值概率存在两倍差异,且PI-RADS 4和5对应的GG≥2癌症绝对风险分别波动于23%-68%和49%-87%,提示mpMRI标准化亟待加强。

要点

  • 不同中心PI-RADS 4/5赋值概率存在两倍差异,异质性p<0.001
  • PI-RADS 4对应GG≥2癌症风险为23%-68%,PI-RADS 5为49%-87%
  • mpMRI表现与解读差异影响患者咨询、风险分层及临床实践

核心结论

  • 不同机构间PI-RADS 4/5赋值概率及后续GG≥2前列腺癌检出率差异显著,需改进mpMRI操作与解读的标准化。

研究设计与样本

  • 基于前列腺活检协作组多中心回顾性队列,纳入北美、欧洲及亚太13个中心2010-2023年接受mpMRI后前列腺活检、PI-RADS≥3且行MRI靶向活检的患者。
  • 共分析7320例独特患者的7325次活检,采用逻辑回归估计PI-RADS 4/5赋值风险及GG≥2疾病风险。

主要发现

  • 调整患者风险后,不同中心间PI-RADS 4或5赋值概率仍存在两倍差异(异质性p<0.001)。
  • PI-RADS 4对应的GG≥2疾病绝对风险在不同中心间为23%至68%,PI-RADS 5为49%至87%(异质性p均<0.001)。

临床怎么用

  • 临床咨询、风险分层及风险计算器应用需考虑机构间mpMRI表现的差异性。
  • 推动mpMRI操作与解读标准化以降低机构间变异。

局限性

  • 以前列腺活检作为参考标准存在局限性,但反映了mpMRI在临床实践中的典型应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The quality and reporting of prostate magnetic resonance imaging (MRI) are operator dependent, leading to variations in estimates such as positive predictive value across sites. This impacts patient counseling, risk modeling, and risk calculators. This study assessed variation in Prostate Imaging Reporting and Data System (PI-RADS) score classification and subsequent probability of grade group (GG) ≥2 + prostate cancer. METHODS: Data from the Prostate Biopsy Collaborative Group, including multiple sites in North America, Europe, and Asia Pacific, were analyzed. Patients underwent multiparametric MRI (mpMRI) of the prostate followed by prostate biopsy during the years 2010-2023. Only those with MRI-targeted biopsy and PI-RADS score ≥3 were included. The risk of being assigned PI-RADS 4 or 5 and risk of GG ≥2 disease for these scores were estimated using logistic regression. KEY FINDINGS AND LIMITATIONS: The cohort included 7325 biopsies from 7320 unique patients from 13 sites. A two-fold variation in the probability of PI-RADS 4 or 5 assignment across sites persisted even after adjustment for patient risk (heterogeneity p < 0.001 for both). There were significant differences in the absolute risk of GG ≥2 disease for PI-RADS 4 and 5 (heterogeneity p < 0.001 for both), varying between 23% and 68% and between 49% and 87%, respectively. The use of prostate biopsy as a reference standard has limitations but reflects typical usage of mpMRI in clinical practice. CONCLUSIONS AND CLINICAL IMPLICATIONS: The probability of being assigned PI-RADS 4 or 5 and subsequent detection of GG ≥2 disease varies widely between institutions. This impacts counseling, risk stratification, and clinical practice, necessitating better standardization in the performance and interpretation of mpMRI.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Nalavenkata SB, Vertosick E, Briganti A, et al. Variation in Prostate Magnetic Resonance Imaging Performance: Data from the Prostate Biopsy Collaborative Group. Eur Urol Oncol. 2025. PMID: 40318951. doi:10.1016/j.euo.2025.02.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。